FDA Approval And Expanding Network Will Grow US Sleep Market

Key Takeaways

• Recent regulatory approval and a distinctive product profile position Nyxoah for rapid growth and wider market penetration in the evolving sleep apnea landscape.
  
• Expanding clinical adoption, favorable reimbursement trends, and future indications support accelerating revenue, margin expansion, and scalable commercial success.
  
• Legal challenges, rising costs, reimbursement uncertainties, a limited patient pool, and high cash outflows threaten market expansion, revenue growth, and long-term profitability.

Catalysts

A medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).

• The recent FDA PMA approval of Genio, combined with its differentiated label (addressing both positional OSA and absence of CCC contraindication), positions Nyxoah to capture a larger segment of the growing U.S. sleep apnea market; this is likely to accelerate revenue growth as the elderly population and detection rates rise.
  
• Growing physician enthusiasm and a rapidly expanding network of trained surgeons and sleep centers signal strong early demand and scalable adoption potential, pointing to the possibility of compounding sales and eventual operating leverage as commercial infrastructure matures.
  
• The healthcare sector's increasing shift away from CPAP and toward less invasive, patient-preferred therapies aligns well with Nyxoah's unique, non-CPAP approach, supporting future market penetration and, over time, improved gross margins.
  
• Upcoming ACCCESS clinical trial readout in 12 months and potential U.S. label expansion to include CCC patients (expected late 2026/early 2027) could further broaden Genio's addressable market, providing a catalyst for long-term revenue and earnings growth.
  
• Nyxoah's established CPT reimbursement pathway, combined with growing payer education and early pre-authorization approvals, reduces pricing headwinds and supports margin improvement prospects as accounts ramp and coverage expands across the U.S. market.

Nyxoah Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Nyxoah's revenue will grow by 129.9% annually over the next 3 years.
• Analysts are not forecasting that Nyxoah will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Nyxoah's profit margin will increase from -899.1% to the average BE Medical Equipment industry of 4.6% in 3 years.
• If Nyxoah's profit margin were to converge on the industry average, you could expect earnings to reach €5.7 million (and earnings per share of €0.12) by about March 2029, up from -€90.1 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 100.0x on those 2029 earnings, up from -1.3x today. This future PE is greater than the current PE for the BE Medical Equipment industry at 23.3x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.92%, as per the Simply Wall St company report.

Risks

• Intense competition from larger, established players like Inspire Medical-who have initiated a patent lawsuit against Nyxoah-could lead to prolonged legal expenses and delayed market penetration, pressuring revenue growth and net margins.
  
• The company's U.S. commercial expansion is driving significant increases in operating expenditures (SG&A), which may continue outpacing revenue gains in the near-to-medium term, thereby sustaining or widening operating losses and negatively impacting earnings.
  
• Reimbursement coverage remains an execution risk, as widespread payer adoption and favorable coverage decisions are not yet fully established and could take until 2026 or later, potentially limiting near-term revenue growth and cash flows.
  
• Nyxoah's Genio system currently addresses a restricted patient cohort (BMI below 32), and while the influence of GLP-1 drugs could expand eligibility, it also introduces uncertainty about the future size of the addressable market and could indirectly affect long-term revenues.
  
• The company's cash burn rate is substantial (cash reserves dropped from €63M to €43M in one quarter), and with further expected SG&A increases and ongoing R&D and IP litigation spending, there is risk of future dilution or increased debt, which would impact shareholder value and profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of €9.17 for Nyxoah based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €13.0, and the most bearish reporting a price target of just €4.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €121.8 million, earnings will come to €5.7 million, and it would be trading on a PE ratio of 100.0x, assuming you use a discount rate of 7.9%.
• Given the current share price of €2.71, the analyst price target of €9.17 is 70.4% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.